Molecular & Cellular Oncology · 2018 · 15 citations · 7 references
MedicineCancer BiologyOncologyCancer PharmacologyMolecular OncologyPrecision OncologyCancer ProgressionCell-cycle DysregulationOncogenic Signaling PathwaysTargeted Cancer TherapyTargeted TherapyTumor BiologyCdc25 Phosphatase SignalingCdc25 PhosphatasesCell Cycle Checkpoint TargetingPi3k InhibitorsPi3k SignalingPten InactivationTherapeutic Target IdentificationTriple-negative Breast Cancer Therapy
The dual phosphatase CDC25 has recently been identified as a target for diverse triple-negative breast cancers including RB1/PTEN/P53-deficient tumors. Moreover, CDC25 inhibitors effectively synergize with PI3K inhibitors to suppress tumor growth. We discuss these findings and the challenges that lie ahead in bringing CDC25 inhibitors to the clinic.
7
Targeting the Vulnerability of RB Tumor Suppressor Loss in Triple-Negative Breast Cancer
Agnieszka K. Witkiewicz, Sejin Chung, Rachel Brough et al. · Cell Reports · 2018 · 105 citations · Full text
Medicine, Cancer Biology, Oncology +14
Identification of CDC25 as a Common Therapeutic Target for Triple-Negative Breast Cancer
Jeff C. Liu, Letizia Granieri, Mariusz Shrestha et al. · Cell Reports · 2018 · 78 citations · Full text